Staphylococcus aureus News and Research

RSS

Staphylococcus aureus is a spherical bacterium (coccus) which on microscopic examination appears in pairs, short chains, or bunched, grape-like clusters. These organisms are Gram-positive. Some strains are capable of producing a highly heat-stable protein toxin that causes illness in humans.

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Trius Therapeutics, Inc. announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate torezolid phosphate (TR-701), will be presented in poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston September 12-15.

8 Sep 2010

Forest Laboratories' ceftaroline fosamil receives FDA Advisory Committee approval for CABP and cSSSI

Forest Laboratories, Inc. announced that the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee voted 21 - 0 in favor of approval of ceftaroline fosamil for the treatment of community acquired bacterial pneumonia (CABP) and voted 18 - 0 in favor of approval for complicated skin and skin structure infections (cSSSI).

8 Sep 2010

Researchers discover new antibiotics in insect's brain

Cockroaches could be more of a health benefit than a health hazard according to scientists from the University of Nottingham, who have discovered powerful antibiotic properties in the brains of cockroaches and locusts.

7 Sep 2010

Study on bacteria may help to develop treatment method for osteomyelitis

A surface molecule on bacteria that instructs bone cells to die could be the target for new treatments for bone disease, says a scientist speaking at the Society for General Microbiology's autumn meeting today.

7 Sep 2010

Research on bacterial cells may offer new hope for MRSA infection treatment

Selfish bacterial cells that act in their own interests and do not cooperate with their infection-causing colleagues can actually reduce the severity of infection.

7 Sep 2010

Lytix Biopharma granted Hungarian approval for Lytixar Phase IIa clinical trial in Gram positive skin infections

The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval in Hungary to commence a Phase IIa clinical trial with Lytixar (LTX-109) treatment of skin infections caused by Gram positive bacteria.

2 Sep 2010

WPI researchers: Cranberry juice cocktail blocks strain of S. aureus

Expanding their scope of study on the mechanisms of bacterial infection, researchers at Worcester Polytechnic Institute have reported the surprise finding from a small clinical study that cranberry juice cocktail blocked a strain of Staphylococcus aureus (S. aureus) from beginning the process of infection.

2 Sep 2010

Neutralizing key toxin associated with Staph aureus bacteria reduces severity of skin and soft-tissue damage

Scientists from the National Institutes of Health and University of Chicago have found a promising treatment method that in laboratory mice reduces the severity of skin and soft-tissue damage caused by USA300, the leading cause of community-associated Staphylococcus aureus infections in the United States.

2 Sep 2010

Scientists report frog skin contains new genera of antibiotics

Kissing a frog won't turn it into a prince except in fairy tales but frogs may be hopping toward a real world transformation into princely allies in humanity's battle with antibiotic-resistant infections that threaten millions of people worldwide. Scientists today reported that frog skin contains natural substances that could be the basis for a powerful new genre of antibiotics.

30 Aug 2010

Coalition of organizations request FDA to govern antibiotic usage in food animal production

Today a broad coalition of organizations hand-delivered the U.S. Food and Drug Administration (FDA) more than 180,000 letters responding to the agency's request for comments on rules governing the use of antibiotics on industrial farms.

27 Aug 2010

AdvanSource receives patent for Antimicrobial Polyurethane Resins to eradicate MRSA

AdvanSource Biomaterials Corporation, a leading developer, manufacturer and seller of advanced polymer technologies and materials for a broad range of medical devices, today announced that it has received a "Notice of Allowance" from the U.S. Patent and Trademark Office in connection with its antimicrobial patent application filed in June 2007. U.S. Patent No. 7,772,296, which is entitled "Antimicrobial Polyurethane Resins and Products Made Therefrom," covers a drug-free, antimicrobial technology to eradicate Methicillin-resistant Staphylococcus aureus ("MRSA") clinical infections associated with medical devices.

26 Aug 2010

Pen-size plasma sterilization device

Prof. Jiunn-Der Liao of Department of Materials Science and Engineering at National Cheng Kung University (NCKU), Tainan, Taiwan, has led Post Doctorate Chih-Chiang Weng and a research team to develop a pen-size plasma sterilization device which can sterilize instruments and wounds by relying on the process of plasma sterilization.

25 Aug 2010

Montana State University offers new biomedical technologies for prevention, treatment of viral infections

Researchers at Montana State University have developed six new biomedical technologies that could have applications for treating antibiotic resistant infections, fungal infections and viral infections; boosting humans' innate immunity and improving scientists' ability to study such compounds. The technologies are available for licensing to interested companies and entrepreneurs.

19 Aug 2010

Policies, practices concerning MRSA differ among acute-care hospitals in the U.S.: Researchers

Hospitals vary in how they detect and treat drug-resistant staph infections, but most follow national guideline recommendations, according to researchers at the University of Illinois at Chicago.

18 Aug 2010

Report cards, disclosures readied or deleted on hospital infections in some states

After several years of delay, Illinois has begun posting hospital infection data on its 'hospital report card' website, including facilities in the greater St. Louis area. State officials say the website — www.healthcarereportcard.illinois.gov — will benefit not only the consumer but also the health care industry. … So far, Illinois reports rates for only central line associated bloodstream infections in hospital intensive care units that occurred last year.

17 Aug 2010

Studies provide evidence for new approach to MRSA vaccines

Two recent studies provide evidence for a new approach to vaccines to prevent infections caused by drug-resistant Staphylococcus aureus -- better known as MRSA - the leading cause of skin and soft tissue, bloodstream and lung infections in the United States. One demonstrates a way to counteract the bacteria's knack for evading the immune system. The other shows how to disrupt the germ's tissue-damaging mechanism.

17 Aug 2010

Intercell reports significant increase in second quarter revenue

Today, Intercell AG announced its financial results for Q2 and H1 2010.IXIARO/JESPECT sales increased significantly from EUR 2.4m in Q2 2009 to EUR 5.2m in Q2 2010 Continued focus on growing marketing and sales of product in traveler and military markets

17 Aug 2010

Scientists create nanoscale coating to eradicate methicillin resistant bacteria

Building on an enzyme found in nature, researchers at Rensselaer Polytechnic Institute have created a nanoscale coating for surgical equipment, hospital walls, and other surfaces which safely eradicates methicillin resistant Staphylococcus aureus (MRSA), the bacteria responsible for antibiotic resistant infections.

17 Aug 2010

Hospital staph infection rate drops as national prevention effort steps up

The rate of drug-resistant staph hospital-acquired infections has dropped as the U.S. has stepped up prevention efforts to fight the deadly condition, The Associated Press reports. "The decline was seen in a federal study of methicillin-resistant staph, or MRSA. The bug often causes only a boil or skin infection. But researchers in the study focused on invasive cases that can become deadly, invading the bloodstream, flesh, lungs and bones. Researchers found that in nine metro areas, cases of MRSA (MUR'-suh) fell about 16 percent between 2005 and 2008.

12 Aug 2010

PolyMedix's PMX-60056 Phase 1B/2 dose-ranging clinical study for heparin reversal meets study endpoints

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B/2 dose-ranging clinical study with PMX-60056, a synthetic small-molecule designed to reverse heparin and low molecular weight heparin anticoagulants.

11 Aug 2010

Staphylococcus aureus News and Research

Further Reading

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Forest Laboratories' ceftaroline fosamil receives FDA Advisory Committee approval for CABP and cSSSI

Researchers discover new antibiotics in insect's brain

Study on bacteria may help to develop treatment method for osteomyelitis

Research on bacterial cells may offer new hope for MRSA infection treatment

Lytix Biopharma granted Hungarian approval for Lytixar Phase IIa clinical trial in Gram positive skin infections

WPI researchers: Cranberry juice cocktail blocks strain of S. aureus

Neutralizing key toxin associated with Staph aureus bacteria reduces severity of skin and soft-tissue damage

Scientists report frog skin contains new genera of antibiotics

Coalition of organizations request FDA to govern antibiotic usage in food animal production

AdvanSource receives patent for Antimicrobial Polyurethane Resins to eradicate MRSA

Pen-size plasma sterilization device

Montana State University offers new biomedical technologies for prevention, treatment of viral infections

Policies, practices concerning MRSA differ among acute-care hospitals in the U.S.: Researchers

Report cards, disclosures readied or deleted on hospital infections in some states

Studies provide evidence for new approach to MRSA vaccines

Intercell reports significant increase in second quarter revenue

Scientists create nanoscale coating to eradicate methicillin resistant bacteria

Hospital staph infection rate drops as national prevention effort steps up

PolyMedix's PMX-60056 Phase 1B/2 dose-ranging clinical study for heparin reversal meets study endpoints

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News